...
首页> 外文期刊>Journal of drugs in dermatology: JDD >Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.
【24h】

Similar effectiveness of methyl aminolevulinate and 5-aminolevulinate in topical photodynamic therapy for nodular basal cell carcinoma.

机译:氨基乙酰丙酸甲酯和5-氨基乙酰丙酸甲酯在结节性基底细胞癌的局部光动力治疗中具有相似的功效。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Photodynamic therapy (PDT) for basal cell carcinoma (BCC) is a treatment modality that is increasingly used in dermato-oncology. Currently, 2 topical photosensitizers, 5-aminolevulinate (ALA) and methyl aminolevulinate (MAL) are widely used, but their efficacy in BCC has not yet been compared in a clinical setting. OBJECTIVE: To evaluate the effect, degree of pain, and costs of ALA-PDT versus MAL-PDT in nodular BCC (nBCC). METHODS: Patients suffering from BCC were randomly assigned to either ALA-PDT (n=22) or MAL-PDT (n=21) in a pilot study. In each group, half of the tumors were debulked prior to PDT. Eight weeks after treatment, the therapeutic outcome was checked histologically. Pain scores were assessed using a visual analogue scale. RESULTS: Residual tumor tissue was detected in 6 BCCs of each study group. No significant difference between ALA-PDT and MAL-PDT was found with regard to therapeutic efficacy and pain scores. Of note, however, the costs of MAL-PDT were 6-fold higher than those of ALA-PDT. CONCLUSIONS: In this study we did not observe any differences in short-term efficacy between ALA-PDT and MAL-PDT. Therefore, both ALA and MAL can be equally recommended as topical photosensitizers in PDT.
机译:背景:基底细胞癌(BCC)的光动力疗法(PDT)是一种越来越多地用于皮肤肿瘤学的治疗方式。当前,两种局部光敏剂5-氨基乙酰丙酸酯(ALA)和氨基乙酰丙酸甲酯(MAL)被广泛使用,但尚未在临床上比较它们在BCC中的功效。目的:评估ALA-PDT与MAL-PDT在结节性BCC(nBCC)中的疗效,疼痛程度和成本。方法:在一项初步研究中,患有BCC的患者被随机分配为ALA-PDT(n = 22)或MAL-PDT(n = 21)。在每组中,一半的肿瘤在PDT前已消肿。治疗后八周,通过组织学检查治疗结果。使用视觉模拟量表评估疼痛分数。结果:在每个研究组的6个BCC中均检测到残留的肿瘤组织。在治疗功效和疼痛评分方面,未发现ALA-PDT和MAL-PDT之间有显着差异。但是,值得注意的是,MAL-PDT的成本是ALA-PDT的6倍。结论:在这项研究中,我们没有观察到ALA-PDT和MAL-PDT的短期疗效有任何差异。因此,可以将ALA和MAL均推荐作为PDT中的局部光敏剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号